You are here

Disable VAT on Taiwan

Unfortunately, as of 1 January 2020 SAGE Ltd is no longer able to support sales of electronically supplied services to Taiwan customers that are not Taiwan VAT registered. We apologise for any inconvenience. For more information or to place a print-only order, please contact uk.customerservices@sagepub.co.uk.

Therapeutic Advances in Medical Oncology

Therapeutic Advances in Medical Oncology


eISSN: 17588359 | ISSN: 17588359 | Current volume: 15 | Current issue: 1 Frequency: Yearly

Journal Highlights

  • Gold open access journal – all articles are made freely available online immediately upon publication
  • Rigorous peer review
  • Listed in PubMed and indexed in Web of Science, Science Citation Index Expanded (SCIE) and Scopus
  • Internationally renown, expert Editorial Board and panel of Associate Editors
  • A leading gold open access journal in oncology
  • Over 500,000 full-text article views annually

Therapeutic Advances in Medical Oncology (TAM) is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies in the medical treatment of cancer. Please see the Aims and Scope tab for further information.


This journal is a member of the Committee on Publication Ethics (COPE).

Diversity, Equity and Inclusion Statement

Therapeutic Advances in Medical Oncology (TAM) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the oncology community.

Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.

We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.

We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.

Submission information
Submit your manuscript today at http://mc.manuscriptcentral.com/tao.

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Open access article processing charge (APC) information

Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons licence.

The APC for this journal is currently 2800 USD. The article processing charge for Plain Language Summary is 4500 USD. 

The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.

This journal flipped to open access on September 1, 2016.

Contact

Please direct any queries to oncology@sagepub.co.uk.

Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.

Executive Director
Georgia Patey SAGE Publications Ltd, London, UK
Managing Editor
Joshua Gazmin SAGE Publishing, London, UK
Associate Editors
Rodabe Amaria, MD Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Aditya Bardia, MD Breast Oncology Program and Medical Oncology Division, UCLA Health Jonsson Comprehensive Cancer Center, LA, USA
Giuseppe Curigliano, MD, PhD Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy
Ian D. Davis Monash University, Australia
Karim Fizazi, MD, PhD Institut Gustave Roussy, University of Paris Saclay, France
Sharlene Gill, MD, MPH, MBA, FRCPC Medical Oncology, BC Cancer - Vancouver, University of British Columbia, Canada
Robert Haddad, MD Division of Head and Neck Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
Nadia Harbeck, MD, PhD University of Munich, Germany
Sara Hurvitz, MD, FACP David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, UCLA, CA, USA
Jonathan Ledermann, MBBS, MRCP, MD, FRCP UCL Cancer Institute, University College London, UK
Natasha Leighl, MD Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
Javier Martin-Broto, MD, PhD, ASCO, ESMO Fundacion Jimenez Diaz University Hospital, Madrid, Spain
Keunchil Park, MD, PhD Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, TX, USA
Matthias Preusser, MD, PhD, EORTC, EANO, ESMO Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria
Liang Qiao, PhD, EASL, ASSCR, CRA The University of Sydney, Westmead, Australia
Rachel Riechelmann, MD, PhD, ESMO, SLAGO, LACOG Clinical Oncology Department, AC Camargo Cancer Center, Sao Paulo, Brazil
Rachna Shroff, MD, MS, FASCO University of Arizona Cancer Center, University of Arizona College of Medicine – Tucson, AZ, USA
Ross Soo, MBBS, FRACP, FAMS, ASCO, IASLC, SSO Department of Haematology-Oncology, National University Cancer Institute, Singapore
Srikala Sridhar, MD, CCTG Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
David Tan, PhD American University of the Middle East, Kuwait and Macquarie University, Australia
Hanneke van Laarhoven, MD, ESMO Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands
Arndt Vogel, MD, ESMO, ASCO, EASL Toronto General Hospital and University of Toronto, Canada
Breast cancer editorial board members
Carlos Barrios, MD Latin American Cooperative Oncology Group (LACOG), Oncoclínicas, Porto Alegre, Brazil
Evandro De Azambuja, MD, PhD Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Belgium
Alessandra Gennari, MD, PhD Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
Kevin Kalinsky, MD, MS Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, USA
Sung-Bae Kim, MD, PhD Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Bora Lim, MD Division of Cancer Medicine, The UT MD Anderson Cancer Center, TX, USA
Miguel Martín, MD, PhD Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
Nicholas McAndrew, MD, MSCE Division of Hematology/Oncology, UCLA David Geffen School of Medicine, CA, USA
Yeon Hee Park, MD, PhD Sungkyunkwan University School of Medicine, Seoul, Korea
Sagar Sardesai, MD, MPH Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, OH, USA
Cristina Saura, MD, PhD Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Spain
Peter Schmid, FRCP, MD, PhD Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK
Priyanka Sharma, MD Division of Medical Oncology, University of Kansas Medical Center and Drug Discovery, Delivery and Experimental Therapeutics program, University of Kansas Cancer Center, USA
Rebecca Shatsky, MD Comprehensive Breast Health Center, University of California San Diego, USA
Laura Spring, MD Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Paolo Tarantino, MD Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Sara Tolaney, MD, MPH Division of Breast Oncology, Dana-Farber Cancer Institute, MA, USA & Harvard Medical School, MA, USA
Neelima Vidula, MD Massachusetts General Hospital Boston, USA
Nikhil Wagle, MD Genentech, South San Francisco, California, USA
Seth Wander, MD, PhD Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Yoon-Sim Yap, MBBS, FRACP, PhD National Cancer Centre Singapore, Duke-National University Singapore (Duke-NUS), Singapore
Central Nervous System Tumors
Priscilla Brastianos, MD Central Nervous System Metastasis Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Enrico Franceschi, MD Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
Patrick Roth, MD University Hospital Zurich, Department of Neurology and Brain Tumor Center Zurich, Switzerland
Genitourinary Cancer Editorial Board members
Giulia Baciarello, MD Department of Medical Oncology, S. Camillo-Forlanini Hospitals, Rome, Italy
Elena Castro, MD, PhD Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
Kim N Chi, MD, FRCPC University of British Columbia, Vancouver, BC, Canada
Toni K Choueiri, MD Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Maria De Santis, MD Charité University Hospital, Germany
Tim Eisen, PhD Cambridge University, Cambridge, UK
Felix Feng, MD Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
Matt Galsky Tisch Cancer Institute, USA
Pooja Ghatalia, MD Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Petros Grivas, MD PhD Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, United States
Lisa G. Horvath, MBBS, FRACP, PhD Department of Medical Oncology, Chris O’Brien Lifehouse, University of Sydney, Sydney, Australia
Maha Hussain, MD, FACP, FASCO Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, USA
Lorena Incorvaia, MD, PhD Department of Biomedicine, Neuroscience and Advanced Diagnostic (BiND), Section of Medical Oncology, University of Palermo, Italy
Ravindran Kanesvaran, MD, MRCP, FAMS Division of Medical Oncology, National Cancer Centre Singapore, Singapore
Alicia Morgans, MD, MPH Harvard Medical School/ Survivorship Program, Dana-Farber Cancer Institute, Boston, MA
Kent Mouw, MD, PhD Dana-Farber Cancer Institute/Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, USA
Jones Nauseef, MD, PhD Convergent Therapeutics, Boston, MA; Weill Cornell Medicine, New York, NY, USA
Anna Patrikidou, MD, PhD Department of Cancer Medicine, Gustave Roussy Institute, University of Paris Saclay, Villejuif, France
David Quinn, MBBS (Hons I), PhD, FRACP, FACP University of Minnesota, USA
Marniza Saad, FRCR, MBBCh Department of Clinical Oncology, Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia
Scott Tagawa, MD, MS, FACP, FASCO Weill Cornell Medicine, New York, NY, USA
Ben Tran, MBBS Peter MacCallum Cancer Centre, Australia
Gastrointestinal Cancer Editorial Board members
Thomas Aparicio, MD, PhD Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, Gastroenterology and Digestive Oncology Department, Université de Paris Cité, Paris, France
Dirk Arnold, MD Asklepios Tumorzentrum Hamburg, AK Altona
Eishi Baba, MD, PhD Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Japan
Irit Ben-Aharon, MD, PhD Fishman Oncology Center, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel
Sakti Chakrabarti, MD Division of Hematology and Medical Oncology at UH Seidman Cancer Center, Case Comprehensive Cancer Center, and Case Western Reserve University, OH, USA
Stephen Chan, MBBS, MRCP, FHKCP, FHKAM, FRCP, FRCP The Chinese University of Hong Kong, Hong Kong
Yun Dai, MD Department of Gastroenterology, Peking University First Hospital, Beijing, China
Richard Finn, MD Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, CA, USA
Aysegül Ilhan-Mutlu, MD, PhD Division of Oncology, Department of Medicine I, Director of Gastroesophageal Tumors Unit, Medical University of Vienna, Austria
Yumin Li, PhD Lanzhou University and Lanzhou University Second Hospital, China
Jonathan Loree, MD, MS, FRCPC Division of Medical Oncology, BC Cancer, Vancouver, Canada
Teresa Macarulla, MD, PhD Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
Matthew Ng, PhD National Cancer Centre Singapore, Singapore
Radka Obermannová, MD, PhD Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk University, Masaryk Memorial Cancer Institute, Czech Republic
Gerald Prager, MD, PhD Department of Medical Oncology, Medical University of Vienna (MUV) and Comprehensive Cancer Center Vienna, Austria
Lorenza Rimassa, MD Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy
Olivier Rosmorduc, MD, PhD Hepato-Biliary Center, Paul Brousse Hospital, Paris Saclay University, Villejuif, France
Debashis Sarker, MBChB, MRCP, PhD King's College London, UK
Thomas Seufferlein, MD, PhD Department of Internal Medicine 1, University Hospital Ulm, Ulm, Germany
Rachna Shroff, MD, MS University of Arizona Cancer Center, AZ, USA
Elizabeth Smyth, MD Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Rebecca K.S. Wong, MB, ChB, MSc, FRCP Princess Margaret Cancer Center, University Health Network; Department of Radiation Oncology, University of Toronto, Ontario, Canada
Gynaecological Cancer Editorial Board members
Susana Banerjee, FRCP, MBBS, MA, PhD The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
Elena Ioana Braicu, MD, PhD Department of Gynecology, Charité University Medicine, Campus Virchow, Berlin, Germany
Alexandra Leary, MD, PhD Gustave Roussy Institute, Université Paris Saclay, GINECO group, France
Yeh Chen Lee, MBBS, BMedSci, MPhil[H1], FRACP Prince of Wales and Royal Hospital for Women, NSW, Australia
Rowan Miller, MD, PhD University College London and St Bartholomew's Hospitals, London UK
Natalie Ngoi, MD Department of Hematology-Oncology, National University Cancer Institute, Singapore
Angélica Nogueira Rodrigues, MD, PhD Federal University of Minas Gerais; Latin American Cooperative Oncology Group, Brazil
David O'Malley, MD Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine (OH, USA)
José Pérez-Fidalgo, MD, PhD Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia (Department of Medicine), Valencia, Spain
Bhavana Pothuri, MD, MS Gynecologic Oncology, NYU Grossman School of Medicine, NYU Langone Health, Laura & Isaac Perlmutter Cancer Center NY, NY, USA
Clare Scott, MBBS, PhD The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia
Ronnie Shapira-Frommer, MD Ella Lemelbaum Institute for Immuno-oncology & Melanoma and the Onco-gynecology service, Sheba Medical Center, Ramat-Gan, Israel
Anna Tinker, MD Division of Medical Oncology, BC Cancer, Vancouver, Canada
Rongyu Zang, MD, PhD Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Skin Cancer Editorial Board members
Ana Arance, MD, PhD Department of Medical Oncology, Hospital Clinic Barcelona, Spain
Nikhil Khushalani, MD H. Lee Moffitt Cancer Center & Research Institute, FL, USA
Mark Middleton, MD, PhD Department of Oncology, University of Oxford, Oxford, UK
Yana Najjar, MD Clinical and Translational Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA
April Salama, MD Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, NC, USA
Lung Cancer Editorial Board members
Fiona Blackhall, PhD, FRCP Department of Medical Oncology, The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, UK
Wilfried Eberhardt, MD University Duisburg-Essen, Essen, Germany
Daichi Fujimoto, MD, PhD Internal Medicine III, Wakayama Medical University, Wakayama, Japan
Justin Gainor, MD Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Marina Garassino, MD Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL, USA
Cesare Gridelli, MD S.G. Moscati Hospital, Avellino, Italy
Lizza Hendriks, MD, PhD Department of Pulmonary Diseases, Maastricht UMC+, the Netherlands
Hidehito Horinouchi, MD, PhD Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Ning Li, MD Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, China
Sun Min Lim, MD, PhD Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
Herbert H. Loong, MBBS, FRCP Department of Clinical Oncology and Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong
Shun Lu, MD, PhD Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Laura Mezquita, MD, PhD Medical Oncology Department, Hospital Clinic of Barcelona; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS; Department of Medicine, University of Barcelona, Spain
Zofia Piotrowska, MD, MHS Massachusetts General Hospital Cancer Center, Boston, MA, United States
Jordi Remon, MD, PhD Department of Medicine Gustave Roussy, Villejuif, France
Christian Rolfo, MD, PhD, MBA,Dr.h.c. The Center of Thoracic Oncology at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
Adrian Sacher, MD Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Ming-Sound Tsao, MD, FRCPC Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Paul Wheatley-Price, BSc, MD MBChB, FRCP Department of Medicine, Division of Medical Oncology, University of Ottawa, ON, Canada
Antoinette Wozniak, MD, FACP, FASCO UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
Neuroendocrine Cancer Editorial Board members
David Chan, MBBS PhD University of Sydney, Sydney, Australia
Barbara Kiesewetter, MD Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
Head and Neck Cancer Editorial Board members
Melvin Chua, MBBS, FRCR, PhD, FAMS Department of Head and Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore and Duke-NUS Medical School, Singapore
Thorsten Füreder, MD Department of Medicine I, Division of Oncology, Medical University Vienna, Austria
Narayanan Gopalakrishna Iyer, MD, PhD, FRCS National Cancer Center Singapore
Brigette Ma, MBBS(Hon.), FRACP, FHKCP, FHKAM, MD(CUHK) State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Hong Kong SAR, China
Jun Ma, MD, PhD Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, China
Sarcoma Editorial Board members
Albiruni Abdul Razak, MB, MRCPI, CCT Princess Margaret Cancer Centre, Toronto, Canada
Matías Chacón, MD Instituto Alexander Fleming, Buenos Aires, Argentina
Tom Wei Wu Chen, MD, PhD Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
Alessandro Gronchi, MD Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Bruno Vincenzi, MD, PhD University Campus Bio-Medico, Rome, Italy
Biostatistical Editors
Kathleen Boyd, MSc PhD Health Economics & Health Technology Assessment, School of Health & Wellbeing, University of Glasgow, UK
Marc Buyse, ScD, ISCB International Drug Development Institute (IDDI), and Hasselt University, Belgium
Antonio Galvano, PhD Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
Susan Halabi, PhD Department of Biostatistics and Bioinformatics, Duke University Medical Center and Duke Cancer Institute, NC, USA
Caroline Kelly, MSc, BSc Cancer Research UK Glasgow Clinical Trials Unit, University of Glasgow, UK
Andrew Martin, PhD NHMRC Clinical Trials Centre, University of Sydney, Australia
Xiwen (Simon) Qin, PhD University of Hong Kong, Hong Kong
Bhupendra Rawal, MSc Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, MA, USA
Qian Shi, PhD Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
Takeharu Yamanaka Department of Biostatistics, Yokohama City University School of Medicine, Japan
Jinqiu (Jacky) Yuan, MPh, PhD Clinical Research Centre, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
Editorial Reviewer Board
Hamzeh Albaba, MD Cross Cancer Institute, Alberta, Canada
Sandra Danielle Algaze, MD USC Norris Comprehensive Cancer Center, CA, USA
Prof. Fatemeh Ardeshir-Larijani, MD, MSc Winship Cancer Institute, Emory School of Medicine, GA, USA
Ilaria Attili, MD European Institute of Oncology, Milan, Italy
Ryan C. Augustin, MD Department of Medicine, University of Pittsburgh, PA, USA
Rita Balsano, MD IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Italy
Holly Barker, PhD The Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne, Australia
Fernando Augusto Batista Campos, MD Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, SP, Brazil
Anthony Bejjani, MD Division of Hematology/Oncology, VA Greater Los Angeles Health System, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Alice Bernard- Tessier, MD MSc Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France
Christine Bestvina ,MD The University of Chicago Medicine, Chicago, IL, USA
Manali Bhave, MD Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
Daniel Breadner, MSc MD FRCPC Division of Medical Oncology, London Regional Cancer Program, London Health Science Center, ON, Canada
Ciro Celsa, MD, PhD University of Palermo, Italy
Johan Chan, MBBS, FRACP National Cancer Centre Singapore, Singapore
Siu Ching, MBBS Chinese University of Hong Kong, Hong Kong
Niamh Coleman, MD PhD Department of Medical Oncology, St. James's Hospital, Trinity College, Dublin, Ireland
Ciara Conduit, FRACP MBBS Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Rena D. Callahan, MD Santa Clarita Cancer Care, UCLA Health, US
Antonio D’Alessio, MD Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
Michael John Devlin, MD PhD Barts Cancer Institute, Queen Mary University of London, London, UK
Dechao Feng, MD, PhD University College London, UK
Sarah Elizabeth Fenton, MD PhD Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
Michael Flynn, MD PhD Department of Oncology, University College London Hospital, University College London, London, UK
Victor Hugo Fonseca de Jesus, MD, MSc Centro de Pesquisas Oncológicas (CEPON), Brazil
Andrea Fung, MD PhD Department of Oncology, Queen's University, Kingston, ON, Canada
Miguel Garcia-Pardo, MD Hospital Universitario Ramón y Cajal, Madrid, Spain
Ana C. Garrido-Castro, MD Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Rodrigo Gomes Taboada, MD, MSc A.C.Camargo Cancer Center, São Paulo, SP, Brazil
Mohamed Gouda, MD, MSc The University of Texas MD Anderson Cancer Center, Houston, United States
Juan Francisco Grau-Béjar, MD MSc Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Anis Hamid, MBBS Memorial Sloan Kettering Cancer Center, NY, USA
Diana L Hanna, MD USC Norris Comprehensive Cancer Center, CA, USA
Helen Hockings,MB BChir PhD St Bartholomew's Hospital, London, UK
Robert Hsu, MD, MS University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, CA, USA
Hui-Yao Huang, PhD Department of Clinical Trials Center, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Laura Huppert, MD UCSF Helen Diller Family Comprehensive Cancer Center, USA
Gino K. In, MD MPH University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Division of Oncology, Los Angeles, CA, USA
Di (Maria) Jiang, MD MSc FRCPC Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Lawrence Kasherman, BMed MMed (ClinEpi) FRACP Illawarra Cancer Care Centre, Wollongong Hospital and Concord Clinical School, University of Sydney, NSW, Australia
Lucy Boyce Kennedy, MD The Cleveland Clinic Foundation, Cleveland, OH, USA
Edmond Kwan, MBBS FRACP PhD Vancouver Prostate Centre, Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada
Ruth Lauren Sacks, MD Emory University School of Medicine, USA
Jieun Lee, MD PhD Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Jii Bum Lee, MD Yonsei Cancer Center, Yonsei University College of Medicine, South Korea
Kyung-Hun Lee, MD PhD Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, Seoul, South Korea
Nathalie LeVasseur, MD, FRCPC Department of Medical Oncology, BC Cancer, Vancouver, Canada
Pedro Emanuel Rubini Liedke, MD MSc Oncoclinicas Porto Alegre and Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
Jasmine Lim, BSc DPhil Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Jessica J. Lin, MD Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
Marla Lipsyc-Sharf, MD Department of Medicine, Dana-Farber Cancer Institute/Mass General Brigham, MA, USA
Wen-Yang Liu, MD Chinese Academy of Medical Sciences and Peking Union Medical College, China
Fernando López-Campos, MD PhD MSc Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Sara López-Tarruella, MD PhD Medical Oncology Department, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERONC, Geicam, Universidad Complutense, Madrid, Spain
Rebeca Lozano, MD Medical Oncology Department, Complejo Asistencial Universitario Salamanca, Salamanca, Spain
Lucy Ma, MD Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Florit Marcuse, MD PhD Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, Maastricht, Netherlands
Antonio Marra, MD MSc Early Drug Development for Innovative Therapies, European Institute of Oncology IRCSS, Milan, Italy
Kristen A. Marrone, MD Johns Hopkins University School of Medicine, USA
Corinne Maurice-Dror, MD BC Cancer, Vancouver, BC, Canada
Arielle J Medford, MD Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA
Alessandra Merlini, MD, PhD University of Turin, Orbassano (TO), Italy
Vishal Navani, MA (Oxon) MBBS (Lon) MRCP FRACP Tom Baker Cancer Centre, Calgary, Canada & University of Calgary, Calgary, Canada
Romario Nguyen, PhD Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney and Westmead Hospital, NSW, Australia
Angelica Petrillo, MD Medical Oncology Unit, Ospedale del Mare, Napoli, Italy
Quincy SC Chu, MD, FRCPC University of Alberta, Canada
Tomás Reinert, MD PhD Breast Medical Oncology Department - Oncoclinicas – Porto Alegre, Brazil
Daniel S. Childs, MD Mayo Clinic, Rochester, MN, USA
Sarah Sammons, MD Dana Farber Cancer Institute, Boston, MA, USA
Tahlia Scheinberg, MBBS (Hons 1) FRACP Medical Oncology, Chris O’Brien Lifehouse, Camperdown, NSW, Australia
Sandor Schokker, MD PhD Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands
J. Eva Selfridge, MD, PhD University Hospitals Seidman Cancer Center, Ohio, US; Case Comprehensive Cancer Center, Ohio, US
Anthony Serritella, MD Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Michael Shafique, MD Moffitt Cancer Center-USF, Florida, USA
Jie Shen, PhD University of Virginia, USA
Demetria Smith-Graziani, MD, MPH Winship Cancer Institute of Emory University, USA
Alannah Smrke, MD Department of Medical Oncology, BC Cancer, Vancouver, Canada
Tira Tan, MBBS MRCP Division of Medical Oncology, National Cancer Centre Singapore, Singapore
Wei Chong Tan, MBBS (Hons) National Cancer Centre Singapore, Singapore
Huarong Tang, MD Department of Gynecological Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, China
Jacob Thomas, MD USC Norris Comprehensive Cancer Center, California, US
Consuelo Torrini, PhD Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Silke Tribius, MD PhD Hermann Holthusen Institute for Radiation Oncology, Asklepios Hospital St. Georg, Asklepios Tumorzentrum Hamburg, Germany
Erica Tsang, MD MPH FRCPC Princess Margaret Cancer Centre, Toronto, Canada
Robin van Geel, PharmD, PhD Maastricht University Medical Centre, Maastricht, Netherlands
David VanDerWeele, MD PhD Hematology and Oncology, Northwestern University Feinberg School of Medicine and OncoSET Precision Oncology Program, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
Dawei Wu Clinical Trials Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, China
Eun-mi Yu, MD Inova Health System, VA, USA
Irene Yu, MD BC Cancer Surrey, Surrey, BC, Canada
Yongfeng Yu, MD PhD Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Bingnan Zhang, MD Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, TX, USA
Jian-Guo Zhou, MD, PhD The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • Directory of Open Access Journals (DOAJ)
  • ProQuest
  • PubMed Central (PMC)
  • Scopus
  • Manuscript submission guidelines can be accessed on Sage Journals.